Health Catalyst earnings date
Health Catalyst (2YP) Q3 2026 Earnings Report
DE:2YP Q3 2026 EPS Results
- Actual EPS
- -EUR 0.03
- Consensus EPS
- -EUR 0.04
- Beat/Miss
- Beat by +EUR 0.02
- One Year Ago EPS
- EUR 0.05
DE:2YP Q3 2026 Revenue Results
- Actual Revenue
- EUR 50.39M
- Expected Revenue
- EUR 49.59M
- Beat/Miss
- Beat by +EUR 799.55K
- YoY Revenue Growth
- -26.26%
Earnings Announcement Details
- Quarter
- Q3 2026
- Date
- 11/05/2026
- Time
- After Close
- Conference Call
- Thursday, November 5, 2026
Health Catalyst's next earnings date is estimated for March 2, 2027, based on past reporting schedules.
Q3 2026 Earnings Call Audio
Q3 2026 Earnings Slide Deck
No slide deck is available for this earnings event.
Q3 2026 Earnings Call Summary
The call was moderately positive overall. Health Catalyst exceeded third-quarter revenue and adjusted EBITDA guidance, reaffirmed its full-year outlook, expects bookings to exceed the annual target, and highlighted a debt-free balance sheet with approximately $79 million in cash. However, elevated churn, lower gross margins, very low professional services margin, higher-than-expected medical claims costs, and an expected fourth-quarter adjusted EBITDA loss remain significant challenges.
Health Catalyst reaffirmed full year 2026 revenue of $246 million-$249 million and adjusted EBITDA of $18 million-$18.5 million, implying an adjusted EBITDA loss in the fourth quarter of negative $1.8 million to negative $1.3 million; for the full year, it expects overall adjusted gross margin below 50%, adjusted technology gross margin in the low 60s, and adjusted professional services gross margin in the low to mid-teens. It now expects to exceed the high end of its $22 million-$26 million bookings target for the year, expects cash to decline modestly in the fourth quarter, and expects to be generally through the migration-related churn headwinds by the end of 2027.
- Third-Quarter Revenue and Adjusted EBITDA Beat GuidanceThird-quarter revenue was $56.3 million, above the guided range of $55 million-$56 million, and adjusted EBITDA was $779,000, above the guided range of $0-$500,000.
- Full-Year 2026 Outlook ReaffirmedBased on year-to-date performance and Project Nexus cost reductions tracking to plan, management reaffirmed full-year 2026 revenue guidance of $246 million-$249 million and adjusted EBITDA guidance of $18 million-$18.5 million.
- Debt-Free Balance SheetFollowing the Vitalware divestiture and retirement of the credit facility, Health Catalyst is debt-free with approximately $79 million in cash equivalents and short-term investments.
- Healthcare Expertise and Client Relationships Cited as Core StrengthsManagement highlighted the company's deep healthcare expertise, longstanding client relationships, proven measurable outcomes, and technology and solutions spanning clinical quality, financial performance, interoperability, and consumer engagement.
- Bookings Expected to Exceed Annual TargetThe company said it continues to see new bookings and expansion within its existing client base and now expects to exceed the high end of its $22 million-$26 million bookings target for the year.
- Faster Embedded Product Implementation DemonstratedOne client went live on the embedded product approximately 75 days after signing. The client reported that 86% of prescriptions were completed within 24 hours, while call volume declined 8% in the most recent week.
- Retention and Client Value Are Immediate PrioritiesManagement made retention its first priority, emphasizing better understanding of client needs, addressing service gaps, continuing to support technologies clients use today including DOS, offering greater deployment flexibility, and aligning modernization efforts with client priorities.
- Planned Cost Alignment and Disciplined InvestmentThe company plans to align its cost base with the revenue it can support today, evaluate economics across the business, improve efficiency, and invest with discipline in opportunities that can create client value and attractive returns.
- Simplification and Portfolio Integration InitiativeManagement said Health Catalyst has an opportunity to simplify how it presents its technology, data, and healthcare capabilities, improve integration across the portfolio, make solutions easier to deploy alongside clients' existing technology, and help clients realize more value.
- Focus on More Consistent ExecutionThe company is establishing a more disciplined operating cadence, increasing shared accountability and coordination, and bringing product, engineering, and client-facing teams into closer alignment.
- Continued Technology Innovation and Client EngagementHealth Catalyst said it is engaging clients well ahead of renewal, focusing on the outcomes they need, and continuing technology innovation designed around how clients operate to strengthen relationships.
- Board Strengthened with Additional ExperienceThe board was recently strengthened by the additions of Steve Nelson and Tami Reller, alongside existing experience in healthcare delivery, technology, and business transformation.
- Project Nexus Savings Tracking to PlanManagement stated that Project Nexus savings are tracking to plan as part of the strategic initiative to transform the operating model and reposition the business.
- Cash Discipline and Fourth-Quarter Billing SupportManagement said it is applying close scrutiny to spending. Fourth-quarter cash is expected to decline modestly mainly because of vendor-payment timing, including a large hosting-infrastructure prepayment, partly offset by client billings that typically benefit the fourth and first quarters.
DE:2YP Earnings History
| Report Date | Fiscal Quarter | Forecast / EPS | Last Year's EPS | EPS YoY Change | Press Release |
|---|---|---|---|---|---|
| Mar 02, 2027 | 2026 (Q4) | -0.05- | 0.07 | ― | ― |
| Nov 05, 2026 | 2026 (Q3) | -0.04-0.03 | 0.05 | -150.00% (-0.08) | |
| Aug 06, 2026 | 2026 (Q2) | 0.030.04 | 0.04 | 0.00% (+0.00) | |
| May 11, 2026 | 2026 (Q1) | 0.010.02 | 0.01 | 100.00% (+0.01) | |
| Mar 12, 2026 | 2025 (Q4) | 0.080.07 | 0.04 | 100.00% (+0.04) | |
| Nov 10, 2025 | 2025 (Q3) | 0.050.05 | 0.06 | -14.29% (-0.01) | |
| Aug 07, 2025 | 2025 (Q2) | 0.030.04 | 0.11 | -66.67% (-0.07) | |
| May 07, 2025 | 2025 (Q1) | -0.000.01 | 0.04 | -80.00% (-0.04) | |
| Feb 26, 2025 | 2024 (Q4) | 0.070.04 | 0.02 | 100.00% (+0.02) | |
| Nov 06, 2024 | 2024 (Q3) | 0.090.06 | 0.03 | 133.33% (+0.04) |
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
